View Author
patient dopamine agonist dopamine agonists valve disease prolactinoma regurgitation cabergoline hyperprolactinemia prevalence valvular heart disease valvular control study treatment incidence aortic dopamine agonist heart parkinson subject tricuspid group leaflet dopamine agonist-treated hyperprolactinemia grade incidence rate endocrinol valve regurgitation prolactin calcification valvular regurgitation metab abnormality women diagnosis dopamine agonist therapy dopamine agonist treatment pharmacy agonist-treated prescription database netherland number bromocriptine therapy control subjects tricuspid regurgitation idiopathic hyperprolactinemia definition value result dopamine agonist users analysis definition b table aortic regurgitation tricuspid valve incidence rates pharmacy records hyperprolactinemic patients morphology 0.4 duration tr grade dopamine agonisttreated hyperprolactinemia 0.6 record mr grade 2 tests aor grade ergot-derived dopamine agonists dopamine agonist use proportion pergolide lactation motion person-year pharmo network
2 Most Recent Publications
|
Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia
(Article)
Kars, M. Souverein, P. Herings, R.M.C. Romijn, J.A. Vandenbroucke, J.P. Boer, A. de Dekkers, O.M. |
2009-08-01
|
|
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma
(Article)
Kars, M. Delgado, V. Holman, E.R. Feelders, R.A. Smit, J.W.A. Romijn, J.A. Bax, J.J. Pereira, A.M. |
2008-09-01
|
